A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype

B A J Evans, D J Bowen, P J Smith, P E Clayton, J W Gregory

Abstract
Genomic DNA from two families with male limited precocious puberty was examined for mutations of the LH receptor gene. In family 1, several members of the pedigree have FMPP, whereas in family 2 there is only one affected subject. A point mutation (T→C at nucleotide 1192) resulting in substitution of threonine for methionine 398 in the second transmembrane domain of the LH receptor protein was found in both families. In addition, one member of family 1 has the mutation, but no evidence of precocious puberty. All obligate carriers within this family were shown to have the mutation, and it was not detected in 94 chromosomes from unaffected and unrelated white subjects. In family 2, the index case was the only one to have the mutation. A previously unreported neutral dimorphism (C→T at nucleotide 1065) is also described.

(F Med Genet 1996;33:143–147)

Key words: new LH receptor mutation.

Familial male precocious puberty (FMPP, also known as familial testotoxicosis) is an uncommon, gonadotrophin independent cause of precocious puberty, inherited in an autosomal dominant male limited pattern. The condition is characterised by the onset of precocious puberty in the absence of spontaneous nocturnal pulsatile gonadotrophin secretion though a limited gonadotrophin response to the administration of intravenous gonadotrophin releasing hormone may occur.1 The precise causative mechanism is unknown, but the observation of mutations in the luteinising hormone (LH) receptor gene support the hypothesis that constitutive activation of the LH receptor is the pathogenetic mechanism responsible.2,3,7

The LH receptor is a member of the family of glycoprotein hormone receptors which are involved in hormone dependent signal transduction through coupling with guanine nucleotide binding regulatory proteins (G proteins).4 Molecular cloning has shown an LH receptor protein that consists of seven transmembrane domains, four cytoplasmic domains consisting of three cytoplasmic loops and the C-terminus, and four extracellular domains consisting of three loops and the N-terminus.9,10

Ligand binding causes a change in the conformation of this family of receptors, which in turn facilitates G protein binding. This is followed by the exchange of GDP for GTP and the dissociation of the α subunit of the G protein which subsequently activates adenylyl cyclase.

Several recent reports hypothesise that FMPP might be the result of a mutant LH that is activated in the presence of little or no agonist.3,7,11,12 The first paper4 described a single base change that results in substitution of glycine for aspartate at position 578 in the sixth transmembrane helix of the LH receptor in affected subjects from eight different families. Since then, however, other workers4,7,11,12 have reported six different point mutations of the LH receptor gene in familial and sporadic cases of male limited precocious puberty. The region containing these activating mutations includes residues 541–581, and spans part of the fifth transmembrane helix, the intervening third cytoplasmic loop, and the majority of the sixth transmembrane helix. No mutations have been reported outside this region. Laue et al12 concluded that the region spanning nucleotides 1624–1741 of exon 11 of the LH receptor gene is a hotspot for heterogeneous mutations that constitutively activate the LH receptor and cause FMPP.

We therefore searched for mutations in a large portion of the LH receptor gene in two families in whom members had male limited precocious puberty in an attempt to elucidate further the link between mutations of the LH receptor gene and this condition.

Patients
FAMILY 1
The index case (II-2, fig 1B) presented at the age of 7 years with precocious puberty (height velocity 9.6 cm/year, testes 5 and 6 ml, genitalia stage 3, pubic hair stage 2). He was troubled by an undiagnosed blistering and scarring skin condition but had no other abnormal past medical history. Twenty-four hour serum profiling showed no evidence of spontaneous gonadotrophin pulsatility (all LH and FSH concentrations less than 0.5 IU/l) and the response to LHRH stimulation was negligible. Serum testosterone concentrations increased from 1.8 nmol/l to 18.8 nmol/l following human chorionic gonadotrophin stimulation. Magnetic resonance imaging of the brain was nor-
normal. He experienced a marked increase in testicular volume over the next six months and was then treated with cyproterone acetate. His older brother (II-1) is aged 12 years and has no clinical signs of spontaneous puberty. His younger brother (II-3) has albinism and at the age of 5-5 years has early pubic hair and genital development with evidence of testicular enlargement in keeping with precocious puberty. The parents are said to have entered puberty at the normal time but a cousin (II-4) is also reported to have experienced precocious puberty.

FAMILY 2
The index case in this family (fig 1C) developed pubic hair at the age of 2 years. Over the next two years, this increased in amount and was associated with penile enlargement, acne, increased height velocity (13-6 cm/year), and aggressive behaviour. His past medical history was otherwise unremarkable and there was no family history of precocious puberty. At the age of 4-6 years, he had stage 3 pubic hair and genitalia with 7 ml testes bilaterally. Apart from a café au lait patch on the costal margin, there were no other abnormal physical findings. The serum gonadotrophin response to LHRH was negligible (maximum LH 0-8 IU/l and FSH 1-4 IU/l) and adrenal and cranial CT scans were normal. He was therefore treated with cyproterone acetate.

Figure 1  SSCP analysis of part (amplified by primer pair A) of the LH receptor gene from (A) four normal subjects, (B) members of family 1, and (C) members of family 2. The different patterns in (A) are the result of a single dimorphism at nucleotide 1192. This difference is also shown in the patterns obtained with double stranded DNA. The other patterns in (B) and (C) are the result of a point mutation at nucleotide 1192. Both of these changes are also reflected in the patterns obtained with double stranded DNA.

Methods
PCR-SSCP ANALYSIS OF THE LH RECEPTOR GENE
Genomic DNA was isolated by standard methods from peripheral blood obtained from members of the two families described above and depicted in fig 1B and C. The LH receptor gene (nucleotide 951 to 2133') was screened for mutations using PCR-single strand conformation polymorphism (SSCP) analysis. Three pairs of oligonucleotide primers were used to amplify sequences coding for the seven transmembrane domains, as well as the three intracellular and three extracellular loops of the LH protein.

The following primers were used: 1a 5'-TTCTTCCATGCTTGAGAGTG-3'; 1b 5'-GGTGAGGAGTCTAGACAGAAGTTTC-3'; 2a 5'-CACTGCTGGCTTTTCTACTGTATT-3'; 2b 5'-TGAAGGGAGACTGAGATGGCAAAAA-3'; 3a 5'-TTCAACCAGTTCACCAGCATGCGCA-3'; 3b 5'-AGGGCTCTCTTGCCCAAATGAAC-3'.

Amplification was performed in a 10 µl reaction mix containing 1 µg of genomic DNA, 100 µmol/l each dNTP, 2 µmol/l each primer, 0-25 µCi(a³²P)-dATP, 0-5 units Taq polymerase (Promega), and 1 µl 10 x PCR buffer (10 mmol/l Tris-HCl pH 9-0, 0-1% Triton X-100, 50 mmol/l KCl, and 25 mmol/l MgCl₂). Reactions were denatured at 95°C for five minutes and subjected to 30 cycles of 95°C for 60 seconds, 57°C for 60 seconds, and 72°C for 30 seconds. Denatured amplified fragments...
were analysed for single strand conformation polymorphisms on non-denaturing polyacrylamide gels under two sets of conditions. Gels containing 6% acrylamide (acrylamide: bis-acrylamide 37:5:1) and 1 × TBE (90 mmol/l Tris pH 8.3, 90 mmol/l boric acid, 2.5 mmol/l EDTA) were run at 5°C, and those containing 10% glycerol, 6% acrylamide, and 1 × TBE were run at 22°C. All gels were electrophoresed at 25 watts, fixed in 10% acetic acid, and dried overnight before autoradiography. The presence of a mutation was indicated by a shift in the mobility of denatured PCR segments when compared to normal DNA. In some cases SSCP gels were not fixed or dried but covered with saran wrap and subjected to autoradiography. Areas of the gel corresponding to normal or mutant bands were then cut out of the gel, left in TE (10 mmol/l Tris pH 7.4, 1 mmol/l EDTA) buffer overnight, and spun through glass wool to remove the acrylamide gel. The eluate was then subjected to amplification by PCR techniques as described previously and prepared for sequencing as described below.

DNA SEQUENCING OF PCR PRODUCTS
Scaled up versions of the PCR reactions described above were carried out in a total volume of 100 μl and without (α-32P) dATP. Duplicate reactions were pooled and run on a 0.8% low melting point agarose gel in 1 × TAE (4 mmol/l Tris pH 7.8, 500 μmol/l sodium acetate, 100 μmol/l EDTA). The appropriate bands were excised and the DNA purified using the Magic PCR Preps DNA Purification kit (Promega). The eluate was used directly for sequencing reactions with a Dyedideoxy Terminator Cycle Sequencing Kit and a Model 373A DNA Sequencing System (Applied Biosystems). In some cases the eluate was used for a 100 μl asymmetrical PCR reaction with a 5:1 ratio of primers. The product was again purified using the Magic PCR Preps described above and the products sequenced with the limiting or an internal (5'-TTCTAGGCAATGG-3') primer using Sequenase V2.0 (Amersham Life Sciences). Sequencing reactions were modified from those recommended by the manufacturer by the omission of the labelling reaction; Sequenase, dideoxy dNTPs, and (α-32P)dCTP in reaction buffer were directly added to asymmetrical PCR templates.

DIGESTION OF PCR PRODUCTS WITH NlaIII OR BbsI
Studies of specific mutations in the fragment generated with primers 1a and 1b were performed by restriction enzyme digestion analysis of PCR products. Amplification was carried out as previously described and 10 μl of the reaction mixture digested with PmlII or BbsI (New England Biolabs) as specified by the manufacturers. PmlII and BbsI restriction fragments were separated on agarose gels (3% Nusieve™ 3:1 agarose (Flowgen Instruments) for PmlII, and 4% MetaPhor™ agarose (Flowgen Instruments) for BbsI), and stained with ethidium bromide to allow visualisation of the DNA. The PCR reactions carried out before these restriction enzyme digests were new reactions using stock DNA solutions, in case the other results obtained during the course of the study were the result of PCR generated artefacts.

Results
PCR-SSCP ANALYSIS
PCR-SSCP analysis of DNA fragments amplified with the three pairs of primers described in the methods section showed band shifts with primer pair 1 only. Initial studies showed two different patterns within the normal population (fig 1A) with a third pattern present in nine members of family 1 and one member of family 2 (fig 1B, C).

SEQUENCING OF PCR PRODUCTS
Manual and automated sequencing showed two point mutations in the region amplified by primer pair 1 when the sequences obtained were compared to the published sequences9: (1)

Figure 2 Sequence of part of PCR product (primer pair 1) from (A) a normal control, (B) a heterozygous mutant, and (C) band containing mutation (family 2, II-1) cut from SSCP gel.
a silent dimorphism in the normal population at nucleotide 1065 (C or T, results not shown) which abolishes a BsrI restriction site (results not shown). This dimorphism was shown to be the cause of the two patterns seen on SSCP gels in normal samples (fig 1A). A study of unaffected and unrelated white subjects (94 chromosomes) showed that the frequency of the two alleles C and T at position 1065 is 0·61 and 0·39 respectively, with an expected and an observed heterozygosity of 0·48; (2) a point mutation in nine members of family 1 and one member of family 2 at nucleotide 1192 (T→C) (fig 2) which introduces a PmlI restriction site (fig 3). This mutation causes an amino acid change from methionine to threonine at position 398. In family 1 it was detected in three patients (II-2, II-3, and II-4), two obligate carriers (I-2 and I-4), three other female carriers (I-5, II-5, and II-7), as well as in one apparently healthy subject currently aged 12 (II-1). Owing to this unexpected result with DNA from II-1, a second blood sample was taken and analysed. The results from both samples were identical.

In family 2 the point mutation was only detected in the affected subject. His parents, whose microsatellite repeat markers were compatible with biological maternity and paternity (results not shown), did not show the mutation, indicating the sporadic occurrence of a new mutation. It is highly unlikely that this new mutation is the result of contamination of this sample with DNA from family 1. If such contamination had occurred, the index case in family 2 (II-1) would have a normal allele from his mother and a normal allele from his father, as well as the mutant DNA. From the SSCP results this is not the case, and it is the father's DNA which has mutated at nucleotide 1192. The mutation was not detected in a study of unaffected and unrelated white subjects (94 chromosomes).

Owing to the fact that the region spanning nucleotides 1624–1741 of the LH receptor gene has been reported as a hotspot for mutations that constitutively activate the receptor, we sequenced the region amplified by primer pair 2 (nucleotide 1320–1783) in DNA from two affected subjects (II-2 from family 1 and II-2 from family 2). No mutations were detected.

Discussion
In the current study, we examined the LH receptor gene in two families with precocious puberty. In one family there are three affected members, while in the other, because of the absence of family history of disease, there is apparently sporadic FMPP. In both, we describe a new point mutation (nucleotide 1192) in the LH receptor DNA, which results in the substitution of methionine (non-polar) 398 with threonine (polar) in the LH receptor protein. This amino acid substitution is in the second transmembrane domain of the receptor protein, and it is the first time that a mutation has been reported outside the hotspot region (nucleotides 1624–1741) described in the introduction.

Three male sibs (II-1, II-2, and II-3) from family 1 have been shown to have this methionine 398 to threonine mutation. II-2 was the index case diagnosed as having FMPP at the age of 7 years. II-3 is currently aged 5 years and is now showing early clinical signs of precocious puberty. II-1, however, is now aged 12 years and remains prepubertal. All obligate carriers within the family were shown to have the mutation. Since the mutation was not detected in 94 chromosomes from unaffected and unrelated white subjects and was found in a sporadic case of male precocious puberty, it is probably the cause of FMPP in these two families. Why II-1 is not affected, however, is not understood, and may indicate that other factors influence the clinical presentation of FMPP. It is also interesting to note that the affected subject in family 2 was diagnosed at a much earlier age (4 years) than those in family 1 (7 and 5·5 years). These differences in phenotypic expression may be explained by differences in basal LH receptor activity.

The release of conformational constraints following ligand binding is essential in the activation of G protein coupled receptors. Six human diseases are now thought to be caused by mutations which result in constitutive activation of G protein coupled receptors: retinitis pigmentosa,12 hyperfunctioning thyroid adenomas,17 autosomal dominant toxic thyroid hyperplasia,18 autosomal dominant hypocalcaemia,19 congenital night blindness,20 and FMPP.1,7 Most of these mutations are towards the 3' end of the receptor in regions which code for the third intracellular loop and the sixth and seventh transmembrane domains of the relevant binding protein. The human rhod-
New point mutation in luteinising hormone receptor gene in familial and sporadic male precocious puberty

opsin gene mutation, which results in the substitution of glycine 90 with asparagine and apparently accounts for congenital night blindness, however, is on the second transmembrane helix. It is also worth noting that point mutations in the second transmembrane domain and first cytoplasmic loop of the receptor for murine melanocyte stimulating hormone, which lead to darkened coat colour, have been shown to cause constitutive activation of, or hyper-responsiveness of, that receptor.

In summary, we have identified a previously unreported point mutation of the LH receptor gene in two families with FMPP, one with the inherited form and the other a sporadic occurrence of the condition. Within the family with the inherited form of FMPP, however, one subject has the mutation but is currently prepubertal at the age of 12. This variable phenotype within one family suggests that genetic counselling should be carried out with caution in this condition. A previously unreported neutral dimorphism is also described. Further work in the form of expression studies should now be carried out to confirm constitutive activation of the methionine 398 to threonine mutation. This, in turn, would lead to the study of the three dimensional conformation of the receptor domains involved in ligand binding and G protein activation.

A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype.

B A Evans, D J Bowen, P J Smith, P E Clayton and J W Gregory

J Med Genet 1996 33: 143-147
doi: 10.1136/jmg.33.2.143